论文部分内容阅读
内科临床医师很少能遇到这样的胸膜炎患者,即其既往历及临床特徵可证明他的疾病是由非结核性疾病所引起来的。现在,绝大多数浆液性胸膜炎都被认为是结核病发作的一种特殊现象。从浆液性胸膜炎的治疗经验中,我们有根据这样断言,由于特效药物(链霉素,对氨柳酸,福梯瓦齐)的应用,以前的药物疗法(柳酸钠,柳酸钙,匹拉米董等)已经失掉了自己的价值。当然,当由于胸膜炎的病因或其经过的特点所致而确有这种必要时,偶尔应用几次上述的药物仍然还是可以的。在治疗结核性胸膜炎患者时,亦应该像治疗每一个结核病患者所必须的那样,要实施所有的综合治疗措施(一般的制度,饮食制度,维生素疗法,输血)。在渗出性胸膜炎症状继续发展时向患者体内输注特效药物——链霉素,对氨柳酸和福锑瓦齐——究竟能达到什么目的呢?这些禁物是专门用来消除胸腔内特异发炎(结核性)病灶的。显然,治疗的成效是由于链霉素、对氨柳酸和福梯瓦齐的制菌作
Internal medicine clinicians rarely encounter patients with pleurisy, that is, their past history and clinical features can prove that his disease is caused by non-tuberculous diseases. Now, most serous pleurisy is considered to be a special phenomenon of tuberculosis attack. From the experience in the treatment of serous pleurisy, we have asserted that due to the application of specific drugs (streptomycin, arachidonic acid, futenwazi), previous drug therapy (sodium salicylate, calcium salicylate, horseradish) Lamy Dong, etc.) have lost their value. Of course, when the need arises due to the etiology of the pleurisy or its characteristics, it is still possible to occasionally apply the above-mentioned drugs several times. In the treatment of patients with tuberculous pleurisy, all comprehensive treatment measures (regular system, dietary system, vitamin therapy, blood transfusion) should also be implemented as necessary to treat each tuberculosis patient. What can be achieved by infusion of specific drugs, streptomycin, anisosin and fluvazide, into the patient’s body when exudative pleurisy symptoms continue to develop? These forbiddings are specifically designed to eliminate intrathoracic specificities. Inflammation (tuberculous) lesions. Obviously, the effectiveness of the treatment is due to the bacteriostatic action of streptomycin, anisolic acid, and Fortevazi.